Госпиталь Ruber Internacional
| Түркия | Австрия | Испания | |
| Тік ішек қатерлі ісігінде сәулелік терапия | бастап $7,000 | бастап $12,000 | бастап $10,000 |
| Сүт безі рагында химиотерапия | бастап $1,200 | бастап $15,000 | бастап $3,500 |
| Оментэктомия | бастап $4,500 | бастап $15,000 | бастап $12,000 |
| Кибер-пышақ | бастап $4,750 | бастап $50,000 | бастап $30,000 |
| Да Винчи роботының көмегімен жатырды алып тастау | бастап $11,000 | бастап $16,000 | бастап $12,000 |
HM Hospitales — бұл Мадридте (Испания) орналасқан 7 жетекші испандық клиниканың тобы.
Мамандануы — ересектер мен балалар онкологиясы, неврология, нейрохирургия, кардиология және ортопедия.
2018 жылы 7 госпитальдің 5-еуі Медициналық беделді бақылау ұйымының нұсқасы бойынша Испанияның ең үздік жеке клиникаларының ТОП-ына кірді MERCO.
Жыл сайын HM хирургтары 26 000-нан астам операцияны орындайды, ал мұнда қатерлі ісіктен шамамен 2 500 пациент емделеді.
Dr. Enrique Grande, MD, PhD, MSc, is a medical oncologist with more than 20 years of experience. He is an international expert in genitourinary and neuroendocrine tumors. He directs the Medical Oncology Department and the One Oncology Madrid Cancer Program at QuirónSalud, Spain’s largest private healthcare network. He leads an integrated, multidisciplinary model with access to targeted therapies and clinical trials.
He is a pioneer in precision oncology. He uses molecular profiling and biomarker-based care. He has authored more than 300 peer-reviewed papers. He serves as a principal investigator and sits on steering committees for many international trials. These studies help set standards of care in urothelial bladder and neuroendocrine tumors. He contributes to guidelines and programs at ESMO, ASCO, ENETS, and EAU.
Доктор Хосеба Реболло Лисеаганың онкология саласында 30 жылдан астам тәжірибесі бар. Ол Quironsalud Torrevieja орталығында аналық без обырын емдеудің заманауи әдістеріне маманданған.
Жұмыртқашақ, жатыр мойны және эндометрий қатерлі ісігі бойынша көптеген клиникалық зерттеулердің бас зерттеушісі — доктор Оакнин озық зерттеу нәтижелерін тікелей емдеу практикасына енгізеді.
Dr. Lucía González Cortijo is a medical oncologist with more than 20 years of experience. She has led the Medical Oncology Department at Hospital Universitario Quirónsalud Madrid since 2020. Her focus areas include breast and gynecologic cancers. She also works in precision oncology, targeted therapies, and immunotherapy.
She has been Principal Investigator in more than 20 Phase II–III clinical trials. She has also served as sub-investigator in over 50 international trials. She previously worked at Quirónsalud Madrid from 2009 to 2020. Before that, she was at MD Anderson Cancer Center Madrid from 2002 to 2009.
She holds an MD and a PhD (cum laude) from the Autonomous University of Madrid. She completed her Medical Oncology specialty training at Hospital 12 de Octubre. She also earned a Master’s in Molecular Oncology. She is a member of SEOM, ESMO, ASCO, and GEICAM. She is a university lecturer.
Leading Spanish centers for ovarian cancer include Clinica Universidad de Navarra and Centro Medico Teknon. These facilities hold JCI accreditation and offer advanced technologies like HIPEC and DaVinci robotic surgery. Specialists such as Dr. Ana Oaknin and Dr. Lucia Gonzalez Cortijo lead clinical trials for personalized therapies.
Bookimed Expert Insight: Spain ranks 4th globally in patient requests through our platform, reflecting high trust in its oncology infrastructure. While major centers like Clinica Universidad de Navarra serve 140,000 yearly patients, smaller specialized units often provide faster access to robotic systems. Dr. Ana Oaknin at Hospital Quiron Barcelona is a standout for patients seeking access to global clinical trials.
Patient Consensus: Patients note that traveling to major hubs like Madrid or Barcelona is necessary to access specialized robotic surgery. Those choosing private facilities emphasize the advantage of skipping long wait times common in public systems to begin treatment within weeks.
Spanish oncology centers utilize robotic-assisted systems like Da Vinci Xi and heated chemotherapy (HIPEC) to improve surgical precision. These technologies allow surgeons to perform complex debulking while preserving healthy tissue. Facilities often hold JCI accreditation and Newsweek rankings for clinical excellence.
Bookimed Expert Insight: Data shows a concentration of surgical expertise in Barcelona and Madrid. Centers like Centro Médico Teknon and HM Hospitales Madrid handle over 23,000 operations annually. This high volume allows these facilities to maintain advanced infrastructure like the Da Vinci Xi system. Patients should prioritize clinics with multiple accreditations, such as JCI and EFQM, to ensure consistent safety protocols.
Patient Consensus: Patients note that robotic surgery at private centers in Barcelona and Madrid significantly reduces hospital stays. Many emphasize that while HIPEC isn't universal, it is highly valued for high-recurrence cases.
Spanish oncology centers report a 90% to 95% 5-year survival rate for Stage I ovarian cancer. Advanced cases show approximately 30% to 41% survival at Stage III. Efficacy is driven by specialized surgery and targeted therapies like Olaparib, which reduces progression risk by 70%.
Bookimed Expert Insight: Spain’s oncology landscape is defined by massive patient volumes and specialized academic research. HM Madrid alone serves 2.3 million outpatients annually. This high volume allows doctors like Dr. Ana Oaknin to lead over 100 peer-reviewed trials. Such expertise is vital because Spanish data shows 5-year survival drops from 70% in younger women to 19% in seniors. Choosing a research-heavy center like Clinica Universidad de Navarra ensures access to these trial-based protocols for complex cases.
Patient Consensus: Patients note that while early detection remains difficult, the precision of robotic surgery at major centers is excellent. Many emphasize that religious tracking of CA-125 markers and joining support groups is essential for managing long-term recovery.
Patients should plan to stay in Spain for 14 to 21 days after major ovarian cancer surgery. This includes 3 to 7 days of hospitalization followed by local observation. Most airlines require a medical fit-to-fly certificate if traveling within 14 days of abdominal procedures.
Bookimed Expert Insight: While general medical guidelines suggest a 14-day stay, specialized packages in Madrid like those at Hospital Ruber Internacional recommend up to 45 days for complex recovery. This extended period accounts for advanced molecular profiling and coordination of systemic therapies that often follow surgical debulking.
Patient Consensus: Patients emphasize the need for flexible accommodation near the clinic. They note that common issues like fatigue and gas pain often make the minimum 2-week stay feel rushed.
International patients can join ovarian cancer clinical trials in Spain if they meet specific trial protocols. Facilities like Quironsalud Madrid offer free treatment through trials for eligible candidates. Success depends on tumor markers, previous treatments, and the ability to remain in Spain for long-term monitoring.
Bookimed Expert Insight: Spanish oncology centers handle massive patient volumes, with Clinica Universidad de Navarra serving 700,000 people annually. This high throughput makes Spain a primary hub for Phase II and III trials. Patients should target clinics like Quironsalud Madrid where clinical trials are a noted feature. These institutions often have the infrastructure to evaluate international medical records for trial suitability faster than smaller public hospitals.
Patient Consensus: Patients emphasize that residency and health cards are often bigger hurdles than medical criteria. Many recommend focusing on private research institutes in Barcelona or Madrid to bypass local public system restrictions.
Minimally invasive surgery is a widely available option for early-stage ovarian cancer in Spain. Surgeons use laparoscopic or robotic-assisted techniques to perform staging and fertility-preserving procedures. Centers like Centro Médico Teknon and Hospital Quirón Barcelona utilize the Da Vinci Xi system for high-precision oncological operations.
Bookimed Expert Insight: While major centers like Hospital Universitario HM Madrid serve over 70,000 inpatients annually, specific robotic expertise varies by city. Data shows that Barcelona and Madrid host the highest concentration of JCI-accredited facilities, where surgeons often combine robotized surgeries with advanced diagnostics like PET-CT to ensure complete tumor staging.
Patient Consensus: Patients note that robotic surgery is more accessible at private clinics in Madrid and Barcelona to avoid waitlists. They emphasize checking a surgeon's specific volume of minimally invasive cases before committing to a procedure.
Barcelona and Madrid host the highest concentration of English-speaking oncology teams in Spain. These cities feature JCI-accredited hubs like Centro Medico Teknon and Hospital Ruber Internacional. Specialized departments often employ US-trained specialists. This ensures fluent communication for complex ovarian cancer treatments and clinical trials.
Bookimed Expert Insight: While Madrid and Barcelona are primary hubs, Clinica Universidad de Navarra in Pamplona serves 700,000 international patients. It holds the first US-equivalent JCI certificate in Spain. This indicates a high level of English-speaking infrastructure despite being outside the largest metropolitan areas. This center reports a high 74% cure rate for complex sarcomas.
Patient Consensus: Patients note that choosing private centers helps avoid the need for translators required in public hospitals. Experienced teams in Madrid and Barcelona are specifically praised for explaining PARP inhibitor trials clearly in English.